AFT Pharmaceuticals expects sales to hit analyst forecast of $70 mln

Paul McBeth
Thu, 16 Feb 2017

By Paul McBeth Feb. 17 (BusinessDesk) - AFT Pharmaceuticals, which manufactures the Maxigesic painkiller, expects annual sales to meet analysts' forecasts of about $70 million and has adjusted its loan covenant with shareholder Capital Royalty Group.  The Auckland-based drug maker projects annual sales will rise 9.4 percent in the year ending March 31 and has adjusted the revenue covenant on its CRG loan to meet a sales target of $67.5 million, it said in a statement. AFT had set up a US$30 million six-year facility with CRG in 2014, whic...
Opinion
PATTRICK SMELLIE: What do the Nats do now?
Pattrick Smellie | Tue, 14 Jul 2020

Todd Muller's only job as National Party leader was to lose the election better than it seemed Simon Bridges was destined to do. Whoever replaces Muller has an even simpler task: save as much of th...

Listed Companies
Huljich family sells 25% of Pushpay stake
Dan Brunskill | Tue, 14 Jul 2020

The Huljich family has sold a quarter of its cornerstone stake in Pushpay Holdings, one of the rising software company stars. The 14.4 million shares were sold for $123.8 million, or $8.60 per shar...

Property
Housing market rebounds sharply; caution required
Jenny Ruth | Tue, 14 Jul 2020

The housing market bounded out of lockdown last month with sales volumes the highest for June in four years and prices nationally up 8.6 percent from a year earlier. The Real Estate Institute's lat...

The role of private equity in the wake of COVID-19

As local covid-19 restrictions ease, a new business cycle is beginning in New Zealand.